Are Antimicrobial Peptide Dendrimers an Escape from ESKAPE?

Yayoi Kawano,¹ Olivier Jordan,² Takehisa Hanawa,¹
Gerrit Borchard,² and Viorica Patrulea^{2,*}

¹Laboratory of Preformulation Study, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.

²Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Viorica Patrulea, PhD

Submitted for publication October 16, 2019.
Accepted in revised form March 18, 2020.

*Correspondence: Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1, Rue Michel Servet, Geneva 1205, Switzerland
(e-mail: viorica.patrulea@unige.ch).

Significance: The crisis of antimicrobial resistance (AMR) increases dramatically despite all efforts to use available antibiotics or last resort antimicrobial agents. The spread of the AMR, declared as one of the most important health-related issues, warrants the development of new antimicrobial strategies.

Recent Advances: Antimicrobial peptides (AMPs) and AMP dendrimers (AMPDs), as well as polymer dendrimers are relatively new and promising strategies with the potential to overcome drug resistance issues arising in ESKAPE pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species) colonizing chronic wounds.

Critical Issues: AMPs–AMPDs suffer from limited efficacy, short-lasting bioactivity, and concerns of toxicity. To circumvent these drawbacks, their covalent coupling to biopolymers and/or encapsulation into different drug carrier systems is investigated, with a special focus on topical applications.

Future Directions: Scientists and the pharmaceutical industry should focus on this challenging subject to either improve the activity of existing antimicrobial agents or find new drug candidates. The focus should be put on the discovery of new drugs or the combination of existing drugs for a better synergy, taking into account all kinds of wounds and existing pathogens, and more specifically on the development of next-generation antimicrobial peptides, encompassing the delivery carrier toward improved pharmacokinetics and efficacy.

Keywords: chronic wounds, ESKAPE microbial infection, topical antimicrobials, chitosan derivatives, antimicrobial peptide dendrimers, nanoparticles

SCOPE AND SIGNIFICANCE

MICROBIAL INFECTION HAS become a major global threat due to the emergence of antimicrobial resistance (AMR). This spurred the need for innovative strategies to fight multidrug-resistant (MDR) bacteria.

This review summarizes the most relevant available antimicrobial agents related to topical therapy.

We discuss antiseptics and antibiotics commonly used in wound care and summarize the shortcomings of their application in certain patients. Furthermore, we review innovative strategies relying on linear and dendrimeric antimicrobial peptides (AMPs), including the drug delivery approaches that may improve their efficacy against AMR.

© Yayoi Kawano, *et al.*, 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

TRANSLATIONAL RELEVANCE

Treatment of infections resulting from bacteria belonging to the ESKAPE (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species) collection is a clinical challenge. This article describes commercially available topical antimicrobials and antiseptics, emphasizing their bacterial activity and limitations. Key AMPs tested in clinical trials are presented. To cope with the urgent need for innovative solutions, novel dendrimer peptides, chemical conjugates, and nanocarriers are discussed, which may allow for an improved activity against MDR bacterial infections.

CLINICAL RELEVANCE

The care and management of infected wounds is a burden not only for patients, who suffer from severe pain, but for clinicians as well. AMR remains a critical issue and novel AMPs and AMP dendrimers (AMPDs) offer solutions for eradicating MDR bacteria, allowing healing to occur.

BACKGROUND

Skin has essential roles in maintaining homeostasis, preventing microbial invasion, and providing a barrier between body tissues and the external environment. However, burns, and traumatic or chronic wounds, such as venous, diabetic, and pressure ulcers, compromise the protective barrier that skin offers and subsequently facilitate the risk of bacterial infections.¹ Microbial infection due to AMR is one of the major global threats that continues to worsen despite the efforts in finding solutions. Around 0.7 million people die each year due to the emergence and persistence of MDR bacteria or so-called superbugs.² It is estimated that by the end of 2050, AMR could lead to more than 10 million deaths annually, compared with more than 8.2 million deaths attributable to cancer.²

MDR hinders the healing process in wounds, as most of the wounds would develop infections at some point.¹ One of the most challenging MDR bacteria is *P. aeruginosa*, which is part of the problematic bacterial collection called ESKAPE. Among other virulence factors such as adhesion, quorum sensing, or toxin production, the success of ESKAPE pathogens in escaping from the antibiotic treatment lies in the different posttranslational modifications found in their proteome.³ With the emergence of multidrug-resistant bacteria and re-emerging infectious diseases, development of new antibacterial agents has become an urgent task.

The World Health Organization (WHO) called on member states to act against AMR since 1998. WHO calls for improvement of surveillance and testing systems, appropriate use of antibacterial agents, and strengthening countermeasures against infectious diseases. WHO has recently listed nosocomial ESKAPE among the 12 families of MDR bacteria. Moreover, AMR negatively affects the global economy and especially poor countries where the health care system is underdeveloped.⁴ Recent calculations estimate that by the end of 2050, global MDR costs will go above \$100 trillion.²

Clinical and Laboratory Standards Institute (CLSI) guidelines established a list of available antibiotics specifically active against ESKAPE bacteria (Table 1). Surprisingly, many antibiotics and combination of antibiotics have been removed from the list due to their side effects or lack of efficacy. Even for relatively new antibiotics, incidences of resistance are reported and for some bacteria, such as *A. baumannii*, *K. pneumoniae*, and *P. aeruginosa*, resistance has not yet been overcome. These latter were generally kept in the CLSI guideline. Some antimicrobial agents were added since 2010 due to evidence of absence of resistance against specific strains.

Lastly, AMPs have attracted high interest, since they are less likely to induce MDR. AMPs are short peptides consisting of 10–50 residues and produced by all living forms, including protozoa, bacteria, animals, and humans. They are important mediators of innate immune defense. Their amino acid sequence and secondary structure are diverse, but most of the antibacterial peptides are amphipathic with both basic and hydrophobic clusters, and bacterial cell membranes rich in acidic lipids are used for ATP production. Most AMPs possess cationic properties. They have shown a broad activity against a wide range of pathogens, including MDR bacteria by lysing cell membrane through electrostatic interactions.

However, AMPs are rapidly degraded once in contact with human serum (short plasma half-life), losing their activity and most of them are toxic, besides having high production costs.¹⁶ Another promising approach is the use of AMPDs, which showed better activity than conventional AMPs, but still show quite high toxicity and poor stability in human serum of only a few hours.¹⁷ There is therefore an urgent need to develop new strategies of application of these AMPs and AMPDs avoiding their degradation, while reducing their toxicity at therapeutic concentrations. Chemical conjugation of these potent molecules to different polymers may offer a solution to overcome these

Table 1. Antimicrobial agents against ESKAPE added, removed, or kept from the CLSI guidelines over the period 2010–2019

Pathogen	Available Antibiotics	Efficacy–Resistance Reported	Ref.
<i>Enterococcus faecium</i>	Dalbavancin, Oritavancin, Tedizolid, Telavancin	No resistance reported	5
	Vancomycin	Resistance found	
<i>Staphylococcus aureus</i>	Dalbavancin, Oritavancin, Tedizolid, Telavancin	No resistance reported	6,7
	Ceftaroline	Resistance found	
	Amikacin, Amoxicillin–clavulanate, Ampicillin–sulbactam, Cefaclor, Cefamandole, Cefazolin, Cefdinir, Cefepime, Cefmetazole, Cefonicid, Cefoperazone, Cefotaxime, Cefotetan, Cefpodoxime, Cefprozil, Ceftazidime, Ceftizoxime, Ceftriaxone, Cefuroxime, Cephalothin, Doripenem, Ertapenem, Kanamycin, Imipenem, Loracarbef, Meropenem, Moxalactam, Netilmicin, Oxacillin, Piperacillin–tazobactam, Ticarcillin–clavulanate, Tobramycin	Removed from CLSI guidelines	
<i>Klebsiella pneumoniae</i>	Aztreonam, Cefazolin, Cefepime, Ceftazidime, Cefotaxime, Ceftaroline, Ceftazidime–avibactam, Ceftizoxime, Cefotolozane–tazobactam, Ceftriaxone, Doripenem, Ertapenem, Imipenem, Meropenem	Resistance found	8
	Cephalothin, Nalidixic acid, Ticarcillin	Removed from CLSI guidelines	
<i>Acinetobacter baumannii</i>	Doripenem, Ertapenem, Imipenem, Meropenem	Resistance reported	9–11
	Mezlocillin, Ticarcillin	Removed from CLSI guidelines	
<i>Pseudomonas aeruginosa</i>	Colistin, Doripenem, Imipenem, Meropenem, Piperacillin, Piperacillin–tazobactam, Ticarcillin–clavulanate	Resistance reported	12,13
	Cefoperazone, Cefotaxime, Ceftizoxime, Ceftriaxone, Moxalactam, Ticarcillin	Removed from CLSI guidelines	
<i>Enterobacter</i> spp.	Aztreonam	No resistance reported	14,15
	Cefazolin, Cefepime, Cefotaxime, Ceftaroline, Ceftazidime, Ceftazidime–avibactam, Ceftizoxime, Cefotolozane–tazobactam, Ceftriaxone, Doripenem, Ertapenem, Imipenem, Meropenem	Resistance reported	
	Cephalothin, Nalidixic acid, Ticarcillin	Removed from CLSI guidelines	

CLSI, Clinical and Laboratory Standards Institute.

drawbacks. Still, the exact antimicrobial mechanism of the polymer–peptide conjugate needs to be further evaluated, as there is a lack of clinical studies describing the healing of infected wounds upon application of AMPs or AMPDs.

DISCUSSION

Infection and biofilm formation

In general, microorganisms colonize all open wounds, although not all wounds will show clinical signs of infection.^{18,19} Upon infection, microbes create a cytotoxic environment, which often leads to chronic wounds and eventually to gangrene with successive amputation of the infected limb or even to the death of the patient due to sepsis.²⁰ However, the likelihood that a wound will be infected is not only related to the presence of the microorganisms, but to the depth, size, and location of the wound, as well. For example, purulent secretions or local expressions of inflammation are clear indications that an infection has occurred.¹⁸ Nevertheless, the inflammation may be caused by conditions unrelated to a wound, such as diabetic neuropathy, venous insufficiency, or ischemia.²⁰

As a rule, wounds can be classified as acute or chronic. Acute wounds are a result of an injury, surgery, or the use of intravascular devices. Acute

wounds heal within a very short period of time, following successive phases of inflammation, proliferation, migration of keratinocytes and fibroblasts, and final tissue maturation.²¹ Wounds that fail healing within 3 months through the normal healing process are categorized as chronic.²² This type of wounds show a persistent inflammation phase, which is characterized by a continuous influx of polymorphonuclear neutrophils leading to impaired wound healing.²³

Moreover, as wounds grow deeper and become more complex, they can infect the underlying tissue and bone causing osteomyelitis.²⁴ For instance, surgical-site infections, such as superficial incisional, deep incisional, organ, or interorgan space infections, will show postoperative signs of infection typically within the first 10 days, occasionally only after month(s).²⁵

Diabetic wounds, such as foot ulcer or venous ulcer, result from uncontrolled glycemia, leading to microvascular complications (retinopathy, nephropathy, and neuropathy) and very high incidence of infection.^{20,26} The potential of the wounds to be infected or to heal depends on the surrounding skin and mucous membranes. Actually, the longer the wounds are exposed to the bacteria, the easier it is for the bacteria to proliferate and colonize.

Wounds are ideal hosts for bacterial colonization, providing a warm environment and nutrients. This may lead to local or dangerous systemic infections.²⁷ The propensity for a wound to become infected is directly proportional to the pathogenicity or virulence of the microorganism, and inversely related to both local and systemic resistance of the host.²⁸ Local factors refer to wound size and depth, degree of chronicity, contamination, type of wound, presence of necrotic tissue, anatomic location, and compromised sterilization of the materials; while systemic factors relate to diabetes, obesity, smoking, age, alcoholism, malnutrition, radiation, medication (with steroids, chemotherapy), or inherited neutrophil defects. Usually, infected wounds are accompanied by foul odor, necrotic tissue, wound pain, and impaired healing. It is generally considered that wound colonization occurs at bacterial loads $<10^5$ bacteria per gram tissue and infection when $>10^5$ bacteria per gram tissue are found.²³

Interestingly, critically ill patients have higher rates of MDR microorganisms compared with other patients.²⁹ Most common MDR bacteria are methicillin-resistant *S. aureus* (MRSA), vancomycin-resistant enterococci, and MDR Gram-negative bacteria (*i.e.*, extended-spectrum β -lactamases; AmpC-type β -lactamases, and metallo- β -lactamase).^{30,31} Importantly, a rational administration of topical antimicrobial agents should be considered to prevent any resistance development. For this, the use of systemic antibiotics is indicated only when infection is evident or in case of ascending limb infection, sepsis, or incision wounds spreading cellulitis.³² Bite wounds, depending on their severity, should be treated with oral antibiotics.³³ Care should be taken to limit the duration of antibiotic administration than to the recommended one, to avoid the development of AMR.³⁴

Bacteria within biofilms are 100–1,000 times more tolerant to antibiotics, disinfectants, or mechanical stresses; thus impeding conventional antibiotic therapy and delaying wound healing in chronic infections.³⁵ Pathogenic bacteria amplify the AMR issue by creating a 3D bacterial biofilm network, which can strongly enhance the chronicity of the wounds. Biofilms are formed of communities with a high bacterial cell density that are enclosed in a self-produced matrix of extracellular polymeric substance. This matrix composed of exopolysaccharides, proteins, and DNA confers additional resistance to bacteria.

The formation of biofilm (Fig. 1) begins when planktonic (free swimming) cells find their way to a surface to which they attach, followed by their re-

arrangement to form and mature the biofilm. Biofilm dispersion, also referred as cell detachment, is followed by release of planktonic bacteria that will restart formation of a new biofilm at distant sites.

Examples of biofilm-related infections include colonization of almost any surface, including abiotic surfaces (hospital walls, medical devices, implants, catheters, etc.), as well as of biotic surfaces (surgical sites, wounds, lungs, urinary tract, cardiac tissues, bones, etc.).³⁶

Several mechanisms have been proposed to understand the tolerance of bacteria in biofilms to antibiotic treatment³⁷:

1. Limited antibiotic penetration into the biofilm
2. Gene mutation
3. Reduced metabolic rate, growth rate, and division rate
4. Presence of slowly growing persister cells that could reactivate after the antibiotic treatment
5. Overexpression of bacterial efflux pump in biofilm, which leads to increased resistance to antibiotics
6. Protection by the self-secreted matrix of extracellular polymer substance.

There are few antimicrobial agents in clinical use to specifically target biofilms, probably due to the poor understanding of biofilm formation. Resistance ability can be explained if combining the before-mentioned mechanisms. For instance, *P. aeruginosa*, which frequently leads to biofilm-associated infections, adapts easily to the hostile habitat by producing adapted phenotypes and mutations. On the other hand, the geometry of *P. aeruginosa*'s colonies in a shape of tall ridges or wrinkles (referred as colony rugosity), facilitates their oxygen supply and allow them to grow taller.³⁵

Current biofilm-related infection diagnosis are based on (i) clinical wound characteristics: edema, erythema, warmth, and purulence; (ii) laboratory-based analyses: microbiological tests of wound swabs; and (iii) technical methods: scanning electron microscopy, gas chromatography–mass spectrometry, epifluorescence microscopy, colorimetric methods, and metabolic and biomass assays.³⁸ In the context of AMR, adequate diagnosis and design of efficient treatments against biofilm-associated infection is critically needed.

Topical antimicrobial and aseptic agents

Despite recent advances in wound management, very few topical therapies (Fig. 2) proved their ef-

Figure 1. Biofilm formation, including the four stages: (1) Cell attachment, (2) colony formation, (3) mature biofilm, and (4) dispersion of the cells. Color images are available online.

ficacy in promoting wound healing. They led to a better understanding of factors influencing the process of wound healing and protection against bacterial infection. However, these methods have met with challenges, as well.^{39,40}

Many wound dressings have been developed in an attempt to combine anti-infective properties and promotion of wound healing. Hydrophilic hydrogels and foams absorb wound exudates and keep the wound hydrated. However, they can act as a perfect breeding ground for bacterial growth. Bruises and scrapes result from frequent bandage change, which may lead to new skin in-

juries.⁴¹ Cotton gauze dressing has been considered for years as the standard of wound care, along with many other commercially available products, such as alginates, collagen dressings, regenerated cellulose, and honey, among others. However, the gold standard for treatment of chronic wounds is yet to be identified.⁴² Integration of antibiotics into conventional wound dressings has been of high interest.

Topical antimicrobial agents, including disinfectants, antiseptics, and antibiotics, have the ability to kill microorganisms, inhibit their growth, or reduce their number. Disinfectants are very potent against most microorganisms; however, their high toxicity toward all healthy tissues limits their application to inanimate objects and materials, such as surgical instruments and surfaces. Antiseptics have a broad antimicrobial activity and may be used even for some open wounds, but toxicity was reported as well.⁴³

In contrast, antibiotics have high bactericidal activity through a specific cell-targeting mechanism—still limited by the AMR, which is very common nowadays. Moreover, administration of some antibiotics is accompanied by several side effects, such as pain, rash, cytotoxicity, toxic effects to kidneys, liver, and other organs.⁴⁴ Several studies reported toxic encephalopathy-induced nonconvulsive status epilepticus,⁴⁵ seizures,⁴⁶ chronic myeloid leukemia, and renal failure,⁴⁷ in the case of cephalosporin use.

Chronic wounds are treated using different topical antibacterial or antiseptic formulations with or without antibiotics as listed in Table 2, depending on the severity of the wound. Besides topical agents, treatment with dermal substitutes has shown effective to heal specific wounds. However, these substitutes generally lack the antimicrobial properties required for a durable outcome.

Figure 2. Current treatment methods for skin regeneration. Color images are available online.

Table 2. Commercially available topical antimicrobials and antiseptics, their bacterial activity and limitations

TAA	Formulation(s)	Activity Against Microorganism(s)	Limitations	Ref.
Acetic acid	Solution 0.5%	Gram (+), (–) bacteria	Limited activity against biofilms; <i>in vitro</i> toxicity	48
Amoxicillin	Gel, solution	Gram (+), (–) bacteria	Resistance found	49
Bacitracin	Ointment	Gram (+), less active in Gram (–); resistance found in <i>Enterobacter</i> spp. and <i>Pseudomonas</i> spp.	Allergic reactions; may lead to overgrowth of drug-resistant organisms; cross-sensitization with neomycin; anaphylaxis	50
Cadexomer iodine	Gels, ointment, dressings	Gram (+), (–) bacteria; viruses; high wound exudates absorption	Cytotoxic; postapplication pain; renal failure; thyroid dysfunction; MRSA	51,52
Cephalosporins	Cream, gel, ointment	Gram (+), (–) bacteria	Renal dysfunction; gastrointestinal disorders; hematologic reactions; neurotoxicity; seizures; encephalopathy	45–47
Cerium nitrate	Cream, dressings	Gram (+), (–) bacteria	Methemoglobinemia; hematology alterations; weight loss	53
Chlorhexidine	Solution, sponge, brush, foam	Gram (+), (–) bacteria; less effective against <i>P. aeruginosa</i>	Cytotoxicity; allergic reactions, including anaphylaxis; resistance reported; injury to eyes and middle ear	28
Clotrimazole	Cream, ointment	Yeast; fungi	Recurring infection	54
Fusidic acid	Cream	Gram (+)	Rapid resistance; multiple applications per day	55
Gauze	Vaseline gauze, silicone gauze, sterile gauze	Nonbacterial	Wound drying; creates new injuries on changing; significant pain	56
Gentamicin	Cream and ointment	Gram (+), (–) bacteria	May lead to resistance; multiple application per day; ototoxicity	57,58
Honey	Dressings	Inhibits >50 bacterial species, including some MRSA	Nonmedical honey to be avoided (as it may contain spores)	28,59,60
H ₂ O ₂	Solution, cream	Gram (+), (–) bacteria; fungi; viruses	Cytotoxicity; oxygen gas embolism	61
Mafenide acetate (Sulfamylon)	Cream, solution, ointment	Gram (+), (–) bacteria	Prone to cause pain upon application; allergic reactions	62
Mupirocin	Ointment	MRSA infection	Potential for developing resistance	48
Neomycin	Ointment, cream, powder	Gram (–) and some Gram (+) bacteria	Allergic contact dermatitis; may cause systemic toxicity; ototoxicity; nephrotoxicity	63,64
Neosporin	Ointment	Gram (+), (–) bacteria	Allergen	65,66
Nystatin	Cream	Fungi	Resistance reported	65,67
PHMB	Gel, solution, and dressing	Gram (+), (–) bacteria and fungi	Cytotoxicity; anaphylaxis	68
Polymyxin B (Colistin)	Ointment	Gram (–)	Last-resort; hypersensitivity reactions; neurotoxicity; renal acute tubular necrosis	48,69
Polysporin	Ointment	Gram (+), (–) bacteria and fungi	Potential for allergy if neomycin crosssensitization	65,66
Povidone/iodine	Solution, ointment, surgical scrub, cream, hydrogel	Gram (+), (–) bacteria; viruses; fungi; and yeast	Contact dermatitis; metabolic acidosis; delayed wound healing	70–72
Silver dressings	Foams, nanoparticle gel	Gram (+), (–) bacteria and fungi, including MRSA and VRE	Possible silver staining of tissues; delayed epithelialization (debated)	28,42
AgNO ₃	Cream, solution, sticks	Gram (+), (–) bacteria and fungi	Frequent reapplication due to short acting; methemoglobinemia; allergies; bacterial resistance	48,73
Silver sulfadiazine	Cream	Gram (+), (–) bacteria	Mild skin sensitiveness	74,75
Sodium hypochlorite	Dakin's solution	More active on Gram (+) than Gram (–) bacteria, fungi, and viruses	Cytotoxicity; postgraft bleeding; dissolve clots	76,77
Retapamulin	Ointment	Some Gram (+) and very few Gram (–) bacteria	May cause local reactions; several applications	78
Xeroform petrolatum	Dressing	Gram (+), (–) bacteria; yeast	Disputed antibactericidal activity	79,80
Zinc oxide-Scarlet Red	Fine mesh gauze, cream, ointment	Some Gram (+), (–) bacteria; fungi	Potential irritation	48

+, positive; –, negative; AgNO₃, silver nitrate; H₂O₂, hydrogen peroxide; MRSA, methicillin-resistant *S. aureus*; PHMB, polyhexa-methylene biguanide; TAA, topical antimicrobials and antiseptics; VRE, vancomycin-resistant enterococci.

Alternative agents to antibiotics

Nowadays, we face an urgent need to identify new antibacterial drugs to overcome AMR of different microorganisms.

Antimicrobial peptides

The AMPs, also referred as host defense peptides, were identified as good candidates to limit resistance-induced microorganisms. They are abundant in

prokaryotes (produced by Gram-positive and Gram-negative bacteria) and in all eukaryotic organisms (fungi, algae, plants, insects, and mammals) and well distributed in cells and tissues as the front fighting line against pathogens.⁸¹ The first AMP, a tyrothricin compound was extracted from *Bacillus* strain by Dubos and Gause in 1939 independently from each other in their respective laboratories. It proved to be effective against

pneumococci infection in mice.⁸² Soon after, it was found that the first AMP contained two different molecules: 80% tyrocidine and 20% gramicidin. Tyrocidine was very effective against both Gram-positive and Gram-negative bacteria, despite being highly toxic against mammalian cells.⁸³ Gramicidin was applied for the treatment of infected wounds and especially ulcers during the Second World War.

Inspired by natural AMPs, many synthetic or semisynthetic analogs were recently developed. The main focus is on synthetic AMPs with higher antimicrobial activity and lower risks of toxicity toward host cells than their natural analogs. An online antibacterial peptide database (APD3) lists more than 3,130 AMPs originating from all species,^{84,85} out of which 134 are identified as human host defense peptides with more than 100 of those exhibiting antibacterial activity.⁸⁶ Their classification depends on the charge, length, sequence of amino acids, and their secondary structure as shown in Table 3. They may have either amphiphilic or cationic domains, for example, human AMPs have a net charge range from anionic (rare) to cationic (most often), which ranges from -3 to $+20$.⁸⁶

Considering the critical situation of ESKAPE pathogens, AMPs are used to date as an effective therapy. They have the advantage of fast acting, bactericidal, multifunctional (stimulate the immune system and inhibit bacterial growth), and anti-inflammatory and/or wound healing promotor. AMPs, such as human β -defensins (hBD-1, hBD-2, and hBD-3)⁹⁰ and cathelicidin LL-37,⁹¹ originating from epithelial tissues are factors of the innate immune system. They protect skin from infections caused by several microorganisms, such as *K. pneumoniae*, MRSA, *P. aeruginosa*, *Escherichia coli*, and *Neisseria gonorrhoeae*.⁹²

Moreover, LL-37 is reported as a safe agent for clinical use as it successfully showed promotion of wound healing in hard-to-heal venous leg ulcers during short-term treatment.⁹³ Histatin 5, human salivary peptide, has a strong antibacterial activity ($\geq 70\%$) against five out of six ESKAPE pathogens, except *K. pneumoniae*. It also showed a strong

in vitro antibiofilm formation in *P. aeruginosa* (60% killing) but less in *A. baumannii* and *S. aureus*.⁹⁴

Cellular distress is usually noticed when exposing bacteria to antibiotics, although no bacterial adaptation nor resistance development was shown when treating *E. coli* for several hours with AMPs, such as cecropin A, melittin, magainin II, pexiganan, and LL-37 at 50% minimal inhibitory concentration (MIC). Also, treatment with these AMPs did not show any changes in mutation rate nor differential expression of genes related to stress-induced mutagenesis, while ampicillin, ciprofloxacin, and kanamycin antibiotics increased the mutation rate by threefold to fourfold.⁹⁵

Bacterial resistance to AMPs and virulence was noticed in case of AMP proteolytic degradation. For instance, *S. aureus* together with an aureolysin metalloprotease could degrade LL-37 AMP by cleaving C-terminus bonds of the peptide and in turn contributing to resistance.⁹⁵ ZapA metalloprotease could inhibit bacterial activity of LL-37 and hBD-1 against *Proteus mirabilis*, responsible for urinary tract infections, by at least 7- and 30-fold, respectively. Surprisingly, the same protease did not inhibit the activity of hBD-2, which has differences in amino acid sequence than hBD-1.⁹⁶ *P. aeruginosa*, *Enterococcus faecalis*, and *Streptococcus pyogenes* use a common mechanism to escape α -defensins by secreting extracellular proteoglycans, which releases dermatan sulfate. Released compound further binds to α -defensins by completely inhibiting its activity.⁹⁵

The process of biofilm formation is another mechanism of AMR to escape AMPs. It was reported that the DNA found in *P. aeruginosa* biofilm induces resistances to both polymyxin B and colistin by inducing lipopolysaccharide (LPS) modification.⁹⁵ On the contrary, no resistance was found when treating protease-resistant *P. aeruginosa* biofilms with LL-37.⁹⁷ In spite of these few reported resistance to pathogens, AMPs remain a promising tool to fight resistance, benefiting from their broad activity spectrum and the variety of their mechanisms of action.

Table 3. The four antimicrobial peptide families with their type of conformation and examples

Family Type	Type of Secondary Structure	Examples	Ref.
α -Helix	α -Helical conformation	Cryptdin-4, human intestinal α -defensin HD5 and HD6, LL-37, Magainin 1 and 2, Moricin	87,88
β -Sheet	At least two β -sheets and two to four disulfide bridges	hBD-1, hBD-2, hBD-3, hBD-4, Pg1, Tachyplesin I	88
Loop	Single bond (either disulfide, amide, or isopeptide)	Thanatin	88
Extended family	Neither α -helical nor β -sheets	Indolicidin, Indolicidin analog (CP10A), Tiritpticin	89

hBD, human β -defensin; Pg1, protegrin-1.

Antimicrobial peptides mechanism of action

Bacteria fall into two main categories depending on their cell wall structure: Gram-negative and Gram-positive bacteria. Gram-positive cells have an outer bacterial cell wall; whereas Gram-negative possess an additional outer membrane adapted with several porins and LPSs. These differences in the cell membrane will confer different susceptibility to various antimicrobial agents.⁹⁸ For instance, some of the AMPs were reported to be more effective against Gram-negative than Gram-positive species.

Even though the mechanisms of action are currently debated among scientists, most agree on the key role of electrostatic forces between positively charged AMPs and negatively charged bacterial membrane, which in turns leads to bacterial leakage and death.⁹⁹ Other proposed mechanisms are: (i) disruptive, such as “barrel-stave” and “toroidal pore” models of pore formation in the bacterial membrane; “carpet-detergent,” by which peptides can form micelles with the membrane components, (ii) nondisruptive, for example, bacterial membrane thinning, depolarization, or aggregation, and (iii) mediated by the “stringent response,” which is the stress response by the bacteria, involving secondary messenger metabolites.⁹⁸ A detailed description of the modes of action is given by Bahar and Ren¹⁰⁰ In addition, the AMP mechanisms of action depend on their concentration, pH, or temperature.^{99,101}

Antimicrobial peptides toxicity and efficacy: preclinical and clinical data

Despite their high and broad antimicrobial activity, AMPs may suffer from their toxicity toward mammalian cells. Toxicity against red blood cells (RBCs), or the ability of AMPs to lyse RBCs, also referred as hemolysis, is another major concern. Therefore, the selectivity toward bacterial cells is generally defined by the ratio of HC_{50}/MIC , where HC_{50} is the concentration necessary to lyse 50% of RBCs and MIC is the minimal concentration to inhibit the growth of a given microorganism, for example, to obtain a bacteriostatic effect.¹⁰² Another important parameter is the minimal bactericidal concentration (MBC) of AMPs, which indicates the ability to eliminate (kill) bacteria. Antibacterial agents are usually regarded as bactericidal if the MBC is no more than four times the MIC.¹⁰³

For the clinical use of AMPs, one should consider their mechanisms of action, stability under physiological conditions, and the balance between their efficacy and toxicity. Currently, only some AMPs with the ability to combat MDR bacteria have been approved by the FDA and already routinely used, such as Gramicidin (date of approval: 2005),¹⁰⁴

Micafungin (2005),¹⁰⁵ Anidulafungin (2006),¹⁰⁶ Telavancin (2009),¹⁰⁶ Ceftriaxone (2010),⁵ Dalbavancin (2014),¹⁰⁶ Oritavancin (2014),¹⁰⁶ Caspofungin (2017),¹⁰⁶ Ozenoxacin (2017),⁵ Tedizolid Phosphate (2015),⁵ and Omadacycline (2018).⁵ Most of them are against bacterial infection and administered either I.V. or topically.^{107,108} Some AMPs, not yet FDA approved, are being tested in clinical trials and listed in Table 4.

Most of the AMPs cannot reach the clinical phase due to their systemic toxicity, fast degradation, short half-life, and/or reduced activity in the presence of salts or divalent cations.¹²² Several AMPs in clinical trials failed to show a better activity than conventional antibiotics or exhibited adverse side effects, although in general one should consider the trade-off between toxicity and efficacy. Some examples are Isegran (withdrawn after phase III) intended for the treatment of oral mucositis^{117,123} and Omiganan (withdrawn after phase III), a topical gel for prevention of catheter infections, acne and rosacea.^{122,124} These failures have spurred the development of encapsulation strategies of AMPs into different delivery systems, such as nanoparticles and liposomes, to enhance their stability and half-life.

Besides clinically approved antimicrobial and antiseptic agents, synthetic dendritic polymers and peptide dendrimers have recently shown promising developments, detailed in the dedicated paragraph below. In addition, other approaches such as encapsulation into nanocarriers or chemical coupling to other molecules are used to reduce AMPs toxicity and increase their efficacy.

Polymer dendrimers for topical application

Poly(amidoamine). Synthetic poly(amidoamine) (PAMAM) dendrimers are available up to the 10th generation and mostly studied for their possible antimicrobial efficacy. The most common polymeric dendrimers are PAMAM, polypropyleneimine, poly-L-lysine, carbosilane, polyglycerol, poly(benzyloxy ether), and phosphorus dendrimers.¹²⁵ Polymer dendrimers have a three-dimensional structure with different density of functional groups and have been found as effective antibacterials. Starting from the inner core of the dendrimer toward the external side, each step of ramification is identified as a generation (G_x), as illustrated in Fig. 3.

The modification of one unit will affect the properties of the whole dendrimer construct. Calabretta *et al.* have reported for the first time the effectiveness of fifth-generation (G_5) amino-terminated PAMAM dendrimers against both *P. aeruginosa* and *S. aureus* at very low concentra-

Table 4. Novel antimicrobial peptides for topical application tested in preclinical and clinical trials to eradicate multidrug-resistant bacteria

Peptide	Producer	Description	Application	Administration	Phase	Comments	Ref.
Brilacidin®	Innovation Pharmaceuticals, Inc.	Defensin mimetic	Acute skin and soft tissue infections in oral mucositis	I.V.	>II	Reduces oral mucositis in HNC patients	109,110
Dusquetide (SGX942)	Soligenix	First-in-class innate defense regulators	Oral mucositis	I.V.	III	Significantly reduces oral mucositis in HNC patients	111
hLF1–11	AM-Pharma	Lactoferricin-based peptide	Bacterial and fungal infections and for prophylaxis in hematopoietic stem cell transplantation	I.V.	I/II	Low antimicrobial efficacy and stem cell transplantation-associated infections in immunocompromised patients was reported; Company suspended trials	112,113
Human LL-37 (OP145)	ProMore Pharma	Human cathelicidin	Leg ulcer	Topical gel	>II	Significantly better than placebo	93,114
Lytixar (LTX-109)	Lytix Biopharma AM	Synthetic peptidomimetic	Skin infection; nasal colonization with <i>S. aureus</i> and impetigo	Topical hydrogel	I/II	Studies in progress	115
NovariFyn® (NP432)	NovaBiotics	Synthetic peptide	MRSA, <i>P. aeruginosa</i> , <i>Clostridium difficile</i> , <i>A. baumannii</i> , <i>Escherichia coli</i>	Topical	PC	Ongoing studies	116
Novexatin	NovaBiotics	Cyclic cationic peptide	Fungal nail infection	Topical brush	II	Ongoing studies. No side effects reported yet	114
PAC-113	Pacgen; Demegen	Synthetic histatin 3	Oral mouth rinse for Candidiasis in HIV patients	Topical solution	II	High efficacy for oral candidiasis	117
Pexiganan (Locilex® , MSI-78)	Magainin Pharmaceuticals	Magainin 2 analog	Diabetic foot ulcer	Topical cream	III	One of the debated peptide for its poor antibacterial efficacy compared with other antibiotics	16,26,118,119
Polymyxin	Athenex	Cyclic cationic lipopeptides	Urinary tract infection, mucositis, ocular and wound infection treatment	I.M., I.T., I.V., ophthalmic	II/III	Used as a “last resort” due to its high toxicity (neurotoxicity and nephrotoxicity); excluded from CLSI list	120,121

hLF, human lactoferrin fragment; HNC, head and neck cancer; I.M., intramuscular; I.T., intrathecal; I.V., intravenous injection; PC, preclinical.

Figure 3. Schematic representation of branched dendrimers and their delivery systems. Color images are available online.

tions (MIC of 1.5 and 20.8 $\mu\text{g/mL}$, respectively).¹²⁶ However, G₅ PAMAM exerted higher toxicity (25% survival at 10 $\mu\text{g/mL}$) toward human corneal epithelial cells compared with LL-37 (significant toxicity at 25 $\mu\text{g/mL}$), potentially due to the highly branched cationic dendrimers.

Interestingly, a smaller PAMAM generation (G₃) was found to have an enhanced activity against *P. aeruginosa* and *S. aureus* when compared with G₅ PAMAM (G₃: 6.3 $\mu\text{g/mL}$ vs. G₅: 12.5 $\mu\text{g/mL}$), or LL-37 (1.3–12.5 $\mu\text{g/mL}$).¹²⁷ This suggests that the number of amino groups displayed by the dendrimers—higher for G₅ than for G₃—is not the sole factor for the antimicrobial activity observed.

PEGylation of the functional groups in PAMAM dendrimers was reported to reduce both the toxicity and bactericidal activity, while complete polyethylene glycol replacement of functional groups inhibited the activity of the dendrimer against *P. aeruginosa*, most probably due to decreased number of amino groups.^{126,127} Another approach to reduce the toxicity of PAMAM dendrimers is to modify the functional groups into amino-, hydroxyl-, and carboxyl-terminated G₄-PAMAM.¹²⁸

The antibacterial activity against *E. coli* *in vitro* was found to decrease from G₄-PAMAM-NH₂ to G₄-PAMAM-OH to G₄-PAMAM-COOH (IC₅₀ of 3.8 $\mu\text{g/mL}$, 5.4 mg/mL , and 22 mg/mL , respectively). Topical vaginal and cervical application of G₄-PAMAM-OH in a pregnant guinea pig model of chorioamnionitis (intrauterine infection by *E. coli*)

lead to major changes to the outer membrane of *E. coli*, while G₄-PAMAM-NH₂ induced changes to both inner and outer bacterial membranes.¹²⁸ However, G₄-PAMAM-NH₂ was dropped for further potential application due to its very high toxicity, while G₄-PAMAM-OH was barely transported across placental membrane model, suggesting safety for pregnant women.¹²⁹

Lower generation, G₁ PAMAM-disaccharide galabiose modified exhibited a 3,000-fold increased potency against *Streptococcus suis* with an MIC of 0.3 nM. G₁ dendrimer was able to inhibit the adhesion of *S. suis*.¹³⁰ Actually, increasing the number of generations in amino-PAMAM from G₃ to G₇ significantly decreased *in vitro* viability and inhibited differentiation of human neural progenitor cells and damaged DNA at a concentration of 5 $\mu\text{g/mL}$. In contrast, G₀, G₁, and G₂ at the same concentration did not show any cytotoxicity.¹³¹ Therefore, lower generation PAMAM hold promise to improve the efficacy–toxicity ratio of the dendrimers, paving the way to clinical applications.

AMPDs for topical applications

Compared with linear AMPs, AMPDs show a three-dimensional, regularly branched structure built by covalent bonds, a very low polydispersity and a higher density of surface groups.¹⁷ Their structure is very similar to the polymeric dendrimers, except that they have only one-side branches, which makes them more flexible for chemical coupling or incorporation into different delivery

Figure 4. Amino acid sequence in AMPD (e.g., G3KL), which is based on a divalent lysine core whose α and ϵ amines along with leucine double geometrically with each ramification building up a new generation. AMPD, antimicrobial peptide dendrimer. Color images are available online.

systems (Fig. 4). The synthetic flexibility and high density of the functional groups found in AMPDs make them very attractive for use as delivery systems for drugs and bioactive principles. Designing peptide-based agents is strongly supported by the high potency of the AMPDs not only to kill bacteria, but also to reduce the toxicity against mammalian cells.¹³²

The displayed functional groups will govern the mechanism of bacterial killing. AMPDs, which bear charged ends, are believed to act by penetrating the cell membrane inducing leakage of intracellular materials resulting in bacterial death. Therefore, the AMPD mechanism of action against bacteria is related to the number of functional surface groups and their ability to cross the cell membrane.¹³²

AMPDs show increased activity, which is usually attributed to the higher local concentration of bioactive units in such assemblies, and to their greater stability against peptidases and proteases. For instance, dendrimeric peptides

were shown to be selective for microbial surfaces with a broad antimicrobial and low hemolytic activity. A family of AMPDs based on R4 tetrapeptide (RLYR) and R8 octapeptide (RLYR-KVYG), were tested against 10 different microbial strains. Both R4 and R8-based dendrimers of fifth and eighth generation exhibited high activity with MICs $<1 \mu\text{M}$ against Gram-positive and Gram-negative bacteria as well as fungi.¹³³

Besides, these AMPDs were resistant to proteolytic degradation or to protease inhibition, which has been attributed to their dendrimeric structure. A lipodimeric peptide, SB056, was investigated for its antimicrobial activity against a range of bacteria, including Gram-positive and Gram-negative strains. The *in vitro* assays showed high antimicrobial activity with MIC in the range of 2–32 $\mu\text{g}/\text{mL}$ against *A. baumannii*, *Enterobacter cloacae*, *E. coli*, *K. pneumoniae*, and *P. aeruginosa*, which is comparable with the activity of polymyxin B.

The SB056 AMPD showed strong activity against *E. coli* and *S. aureus* strains as well as

strong *Staphylococcus epidermidis* biofilm inhibition.¹³⁴ Further improvements on the amphipathic part of the SB056 resulted in more ordered β -strands with a stronger antimicrobial activity against both Gram-positive and Gram-negative bacteria.¹³⁵ A study on series of tryptophan-ending dendrimers showed that amphiphilic AMPDs can be an effective therapy of *E. coli* infections. Most of the tryptophan-anchored AMPDs were able to inhibit the growth of antibiotic-resistant *E. coli* strains, sometimes better than polymyxin B or even indolicidin, besides showing stability in plasma along with low hemolysis and genotoxicity.¹³⁶

Recently, a novel G3KL (containing repetitive units of lysine and leucine) AMPD showed high potency at low MIC against 35 strains of *P. aeruginosa* (8–32 $\mu\text{g/mL}$), 32 strains of *A. baumannii* (16 $\mu\text{g/mL}$), *E. coli* (8 $\mu\text{g/mL}$), and *K. pneumoniae* (16–64 $\mu\text{g/mL}$).¹⁷ G3KL is a peptide dendrimer of third generation, which acts as a membrane-disrupting agent against bacteria. G3RL (with repetitive units of arginine and leucine) showed lower efficiency than G3KL against *P. aeruginosa* (8–32 $\mu\text{g/mL}$) and *Bacillus subtilis* (11 $\mu\text{g/mL}$). Once in contact with the serum, the biological activity of G3RL is inhibited.¹³²

Moreover, both G3KL and G3RL within biological bandages have shown high efficacy against *P. aeruginosa*, absence of toxicity, and no gene alteration in progenitor fibroblast cells at a concentration of 100 $\mu\text{g/mL}$. Especially G3KL showed enhanced angiogenesis in human umbilical vein endothelial cells and chorioallantoic membrane assays, as a proof of further potency to enhance wound healing.¹³⁷ A second-generation AMPD, such as TNS18, has the same activity as G3KL against Gram-negative bacteria, except *K. pneumoniae* and against Gram-positive MRSA (MIC = 8–16 $\mu\text{g/mL}$).¹⁷

Moreover, D-enantiomeric dendrimers dG3KL and dTNS18 have shown high killing effect against different *P. aeruginosa* biofilm strains (90.2–100%) *in vivo* on larvae.¹³⁸ Therefore, the topology and the sequence of the dendrimers can not only affect their antimicrobial potential, but can also alter their proangiogenic effect, as well. Moreover, the same group of Raymond have developed two different glycopeptide dendrimers: a fucosylated peptide dendrimer (FD2) and two galactosylated dendrimer (GalAG2 and GalBG2), which proved to be potent against *P. aeruginosa* biofilm formation *in vitro*.¹³⁹

The AMPDs show strong potency against multiple bacterial strains and biofilms. Further research is warranted to optimize their delivery to the wounded site, for a potential clinical translation.

Delivery strategies for AMPs

The limitations of AMPs in terms of efficacy, fast degradation, or toxicity require adequate delivery strategies to tackle these challenges. As AMPDs are a relatively new class of antimicrobials, most of the research has been performed on AMPs, which were covalently coupled to biopolymers or encapsulated into nanoparticles or liposomes. The design of AMP nanocarriers could serve as an example of how to render AMPDs even more effective while preserving their bioactivity.

Covalent coupling of AMPs to chitosan–chitosan derivatives

AMPs can be favorable drug candidates to be coupled to biopolymers, such as chitosan or chitosan derivatives to reduce hemolytic effects and/or enhance antibacterial activity, also benefiting from chitosan's bacteriostatic properties. These conjugates have the advantage of increased stability against proteases and peptidases, low immunogenicity, high efficiency and selectivity, and relatively small size that allows AMPs to disrupt bacterial wall.¹⁴⁰

- Anoplin–chitosan: Anoplin (derived from wasp venom) covalently coupled to chitosan showed enhanced *in vitro* bioactivity and absence of hemolysis. The activity of anoplin–chitosan conjugates against *S. aureus* and *E. coli* increased proportionally with their degree of substitution (MIC of anoplin peptide of 1.9 $\mu\text{g/mL}$ against *E. coli*).¹⁴¹
- HHC10–chitosan: Cysteine-HHC10 AMP coupled to chitosan showed enhanced bioactivity against *S. aureus* and *S. epidermidis*; almost no hemolysis and lower toxicity than HHC10 alone.¹⁴²
- hLF1–11–chitosan: Human hLF1–11 covalently coupled to a thiol-derivatized chitosan film lead to a significant increase in *S. aureus* adhesion against implant-related infections.¹⁴³
- Dhvar-5–chitosan: This peptide was immobilized to chitosan films for *S. aureus* elimination.¹⁴⁴

These studies suggest a potential for chitosan–peptide conjugates to improve activity and decrease toxicity compared with the parent peptide. Still, we need further investigations to validate this experimental approach and reveal the mechanisms behind this improvement.

Nanocarrier systems

Encapsulation of peptides into nano- or micro-carriers systems can be an efficient approach to

lower cytotoxicity, preserve activity by reducing their degradation and enhance their selectivity.¹⁴⁵ Among these, liposomes, micelles, polymer nanoparticles, and microparticles have met success for drug delivery. This approach has been applied to some AMPs, potentially improving their pharmacokinetic profile.

Liposomes

Liposomes are self-assembled colloidal systems composed of one or more phospholipid bilayers. They have been studied in the last decades as suitable vehicles for drug delivery due to their encapsulation ability and biocompatibility.¹⁴⁵ Liposomes have the advantage of encapsulating both hydrophobic and hydrophilic compounds. Moreover, these drug release systems may protect AMPs against degradation, decrease cytotoxicity, and enhance their stability and bioactivity. For example, Yang *et al.* incorporated a WLBU2 peptide (24-amino acids) using a modified liposome delivery system with high efficiency against both Gram-positive and Gram-negative bacteria (*P. aeruginosa* and *S. aureus*, respectively) and against *Chlamydia trachomatis*.

Furthermore, WLBU2-modified liposomes were safe to human skin fibroblasts and the activity of the peptide was preserved even in the presence of human serum and blood.¹⁴⁶ This AMP-modified liposome system could be potentially used for local infections. An I.V. injection of tuftsin-loaded liposomes in infected animals resulted in site-specific delivery of AMP and stimulation of liver and spleen macrophage functions against antibacterial-antiparasitic infections, such as tuberculosis and leishmaniasis.¹⁴⁷

Vancomycin and chitosan-loaded liposomes were shown to not only improve the pharmacokinetic profile of the peptide, but to also reduce nephrotoxicity in mice. Injectable vancomycin liposomes showed high antibacterial efficacy against Gram-positive bacterial infections, a sustained release profile, and prolonged systemic circulation.¹⁴⁵ This prevented a vancomycin burst release, which could lead to different side effects.

Micelles

A DP7 (12-amino acids) cationic and hydrophilic AMP, incorporated into a micellar system, showed potent therapeutic benefits in different *in vivo* disease models and proved to be safe through I.V. injection in mice. The AMP-micellar construct showed reduced hemolysis and high antibacterial activity against *S. aureus* both *in vitro* (MIC of DP7-micelles >1,024 µg/mL against *P. aeruginosa*, *S. aureus*, and *E. coli*) and *in vivo*.

In *P. aeruginosa*-infected zebrafish embryos and *S. aureus*-infected mice, DP7-micelles showed high efficacy and therapeutic safety comparable to vancomycin. After an I.V. (80 mg/kg body weight) administration of DP7-micelles, all mice survived and no liver bleeding or pulmonary hemorrhage was observed.¹⁴⁸ These AMP-micelle formulations may potentially be used for bacterial infections (in both Gram-positive and Gram-negative species) as they were shown to significantly stimulate defensive immune reactions *in vivo* as well.

Micro- and nanoparticles

Vancomycin has been loaded into polycaprolactone polymer microparticles to minimize the side effects of vancomycin. These microparticles were coadministered with calcium phosphate bone substitutes for preventing postsurgery infection. The encapsulation of vancomycin into microparticles resulted in prolonged peptide release *in vitro* over several weeks.¹⁴⁹ Vancomycin was successfully encapsulated into poly(lactide-co-glycolide) (PLGA) polymers to prevent external-internal ocular bacterial infections.¹⁵⁰ Thus, vancomycin encapsulated into nanodelivery systems may successfully be used as an alternative treatment of infections caused by MDR bacteria.

Piras *et al.* could formulate an efficient nanoparticles system against *S. epidermidis* by ionic gelation method. Peptide LLPIVGNLLKSLL-amide (called TB) was added to chitosan to form NPs. The encapsulation of TB peptide exhibited high bactericidal properties against *S. epidermidis* strains and significantly reduced the toxicity against mammalian cells.¹⁵¹ Another RBRBR peptide was encapsulated into chitosan NPs by a similar method resulting in an enhanced activity against *S. aureus* and significantly reduced hemolysis and cytotoxicity.¹⁵² Thus, chitosan may act as an antimicrobial activity enhancer and/or significantly limit the toxicity of the AMPs.

d'Angelo *et al.* engineered a colistin-loaded PLGA nanoparticles system for sustained delivery of the peptide against *P. aeruginosa* in lung infection. Colistin encapsulated into PLGA NPs could easily penetrate an artificial mucus layer during the first 6 h and successfully eliminated *P. aeruginosa* biofilm *in vitro* within 72 h at 7.5 and 15 µg/mL.¹⁵³

These few studies of AMPs covalently coupled or noncovalently associated to different biopolymers suggest that AMPs are potent candidates to eradicate MDR bacterial infections at an enhanced antimicrobial activity and lower toxicity. Additionally, achieving optimum drug-AMP loading, using the right and safe polymer, storing the new formulation while preserving the bioactivity and stability of the AMP are definitely to be further evaluated.

SUMMARY

The occurrence of AMR has changed the landscape of the drugs used in clinics, more specifically to treat ESKAPE-related infections. In addition, the complexity of the factors affecting wound healing renders the choice of adequate antimicrobial agents difficult. In this context, alternative strategies to overcome AMR are proposed.

Besides clinically approved antimicrobial and antiseptic agents, synthetic dendritic polymers and novel peptide dendrimers (AMPDs) have recently shown promising results in preclinical models of infection. Further strategies are also available to improve their activity and decrease toxicity compared with the parent peptides: the conjugation with (bio)polymers, or the incorporation into carriers such as liposomes, nano- or microparticles. These strategies may allow for a sustained pharmacokinetic profile and improve the activity against MDR bacterial infections, paving the way toward their use in a clinical setup.

ACKNOWLEDGMENT AND FUNDING SOURCES

No external funding sources were used in the preparation of this article.

AUTHOR DISCLOSURE AND GHOSTWRITING

All authors confirm no conflict of interest and no ghost writers were used to write this article.

ABOUT THE AUTHORS

Yayoi Kawano, PhD, is Associate Professor at Faculty of Pharmaceutical Sciences, Tokyo University of Science, Japan. Her research interests are to incorporate poorly water-soluble drugs into different drug delivery systems, and to evaluate formulations for wound healing. **Olivier Jordan, PhD**, is

TAKE-HOME MESSAGES

- The occurrence of AMR has changed the landscape of the drugs used in clinics, more specifically to treat ESKAPE-related infections.
- Antimicrobial peptidic agents are highly potent with a broad activity against Gram (+) and (–) bacteria and microorganisms.
- AMPs are good candidates to limit resistance-induced microorganisms, benefiting from their broad activity spectrum and the variety of their mechanisms of action.
- The performance of AMPs can be further enhanced by several strategies such as: chemical conjugation to biopolymers or organization in a dendritic structure.
- Nanocarrier technology may further improve pharmacokinetic profile to increase antimicrobial effect and reduce toxicity.
- AMPDs show strong potency against multiple bacterial strains and biofilms. Further research is warranted to optimize their delivery to the wounded site, for a potential clinical translation.

Senior Lecturer at the University of Geneva. His research interests lie in the field of innovative carriers for drug, peptide, or protein delivery based on biopolymers, including hyaluronic acid or chitosan. **Takehisa Hanawa, PhD**, is Professor at the Faculty of Pharmaceutical Sciences of Tokyo University of Science. His research interests are to prepare and apply nanoparticle, hydrogel, and film formulations for various external formulations. **Gerrit Borchard, PharmD, PhD**, is a Full Professor in Biopharmaceutics at the University of Geneva. His group's research focuses on the interaction of drug and vaccine formulations with biological systems, including immunotherapy of cancer and infectious diseases, development and characterization of nanomedicines applied in these indications. **Viorica Patrulea, PhD**, is a postdoctoral fellow at the University of Geneva. She has developed a new technological platform based on her expertise in polymer chemistry and complemented by the knowledge of biological and pharmaceutical aspects of the development of formulations for wound healing and protection against microbial infection.

REFERENCES

1. Ambekar RS, Kandasubramanian B. Advancements in nanofibers for wound dressing: a review. *Eur Polym J* 2019;117:304–336.
2. Jasovský D, Littmann J, Zorzet A, Cars O. Antimicrobial resistance—a threat to the world's sustainable development. *Ups J Med Sci* 2016; 121:159–164.
3. Tiwari V. Post-translational modification of ESKAPE pathogens as a potential target in drug discovery. *Drug Discov Today* 2019;24:814–822.
4. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. *Lancet Inf Dis* 2013;13:1057–1098.
5. Koulenti D, Xu E, Mok IYS, et al. Novel antibiotics for multidrug-resistant gram-positive microorganisms. *Microorganisms* 2019;7:270–294.
6. Nigo M, Diaz L, Carvajal LP, et al. Ceftaroline-resistant, daptomycin-tolerant, and heterogeneous vancomycin-intermediate methicillin-resistant *Staphylococcus aureus* causing infective

- endocarditis. *Antimicrob Agents Chemother* 2017;61:e01235-16.
7. Long SW, Olsen RJ, Mehta SC, et al. PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant *Staphylococcus aureus* isolates. *Antimicrob Agents Chemother* 2014;58:6668–6674.
 8. Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. *Biomed Res Int* 2016;2016:2475067.
 9. Caio C, Maugeri G, Zingali T, et al. Extensively drug-resistant ArmA-producing *Acinetobacter baumannii* in an Italian intensive care unit. *New Microbiol* 2018;41:159–161.
 10. Chuang L, Ratnayake L. Overcoming challenges of treating extensively drug-resistant *Acinetobacter baumannii* bacteraemic urinary tract infection. *Int J Antimicrob Agents* 2018;52:521–522.
 11. Nowak J, Zander E, Stefanik D, et al. High incidence of pandrug-resistant *Acinetobacter baumannii* isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. *J Antimicrob Chemother* 2017;72:3277–3282.
 12. Mohapatra DP, Debata NK, Singh SK. Extensively drug-resistant and pandrug-resistant Gram-negative bacteria in a tertiary-care hospital in Eastern India: a 4-year retrospective study. *J Glob Antimicrob Resist* 2018;15:246–249.
 13. Gill JS, Arora S, Khanna SP, Kumar KH. Prevalence of multidrug-resistant, extensively drug-resistant, and Pandrug-resistant *Pseudomonas aeruginosa* from a tertiary level intensive care unit. *J Glob Infect Dis* 2016;8:155–159.
 14. Kulengowski B, Rutter WC, Campion JJ, et al. Effect of increasing meropenem MIC on the killing activity of meropenem in combination with amikacin or polymyxin B against MBL- and KPC-producing *Enterobacter cloacae*. *Diagn Microbiol Infect Dis* 2018;92:262–266.
 15. Alves PH, Boff RT, Barth AL, Martins AF. Synergy of polymyxin B, tigecycline and meropenem against carbapenem-resistant *Enterobacter cloacae* complex isolates. *Diagn Microbiol Infect Dis* 2019;94:81–85.
 16. Giuliani A, Rinaldi AC. Beyond natural antimicrobial peptides: multimeric peptides and other peptidomimetic approaches. *Cell Mol Life Sci* 2011;68:2255–2266.
 17. Siriwardena TN, Lüscher A, Köhler T, et al. Antimicrobial peptide dendrimer chimera. *Helv Chim Acta* 2019;102:e1900034.
 18. Han G, Ceilley R. Chronic wound healing: a review of current management and treatments. *Adv Ther* 2017;34:599–610.
 19. Lipsky BA, Dryden M, Gottrup F, et al. Antimicrobial stewardship in wound care: a Position Paper from the British Society for Antimicrobial Chemotherapy and European Wound Management Association. *J Antimicrob Chemother* 2016;71:3026–3035.
 20. Frykberg RG, Banks J. Challenges in the treatment of chronic wounds. *Adv Wound Care* 2015;4:560–582.
 21. Patrulea V, Ostafe V, Borchard G, Jordan O. Chitosan as a starting material for wound healing applications. *Eur J Pharm Biopharm* 2015;97:417–426.
 22. Halim AS, Khoo TL, Saad AZM. Wound bed preparation from a clinical perspective. *Indian J Plast Surg* 2012;45:193–202.
 23. Bjørnsholt T, Kirketerp-Møller K, Jensen PØ, et al. Why chronic wounds will not heal: a novel hypothesis. *Wound Repair Regen* 2008;16:2–10.
 24. Fritz JM, McDonald JR. Osteomyelitis: approach to diagnosis and treatment. *Physician Sportsmed* 2008;36:nihpa116823.
 25. Hitchman LH, Smith GE, Chetter IC. Prosthetic infections and high-risk surgical populations. *Surgery (Oxford)* 2019;37:38–44.
 26. Uçkay I, Aragón-Sánchez J, Lew D, Lipsky BA. Diabetic foot infections: what have we learned in the last 30 years? *Int J Infect Dis* 2015;40:81–91.
 27. Strohal R, Mittlböck M, Hammerle G. The management of critically colonized and locally infected leg ulcers with an acid-oxidizing solution: a pilot study. *Adv Skin Wound Care* 2018;31:163–171.
 28. Lipsky BA, Hoey C. Topical antimicrobial therapy for treating chronic wounds. *Clin Infect Dis* 2009;49:1541–1549.
 29. Edwardson S, Cairns C. Nosocomial infections in the ICU. *Anaesth Intens Care Med* 2019;20:14–18.
 30. Wu Y-L, Yang X-Y, Ding X-X, et al. Exposure to infected/colonized roommates and prior room occupants increases the risks of healthcare-associated infections with the same organism. *J Hosp Inf* 2019;101:231–239.
 31. Beceiro A, Tomás M, Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? *Clin Microb Rev* 2013;26:185–230.
 32. Filius PM, Gyssens IC. Impact of increasing antimicrobial resistance on wound management. *Am J Clin Dermatol* 2002;3:1–7.
 33. Contreras-Marín M, Sandoval-Rodríguez JI, García-Ramírez R, Morales-Yépez HA. Mammal bite management [in Spanish]. *Cir Cir* 2016;84:525–530.
 34. Pouwels KB, Hopkins S, Llewelyn MJ, et al. Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines. *BMJ* 2019;364:1440.
 35. Omar A, Wright JB, Schultz G, Burrell R, Nadworny P. Microbial biofilms and chronic wounds. *Microorganisms* 2017;5:E9.
 36. Konai MM, Bhattacharjee B, Ghosh S, Haldar J. Recent progress in polymer research to tackle infections and antimicrobial resistance. *Biomacromolecules* 2018;19:1888–1917.
 37. Rabin N, Zheng Y, Opoku-Temeng C, et al. Biofilm formation mechanisms and targets for developing antibiofilm agents. *Future Med Chem* 2015;7:493–512.
 38. Ashrafi M, Novak-Frazer L, Bates M, et al. Validation of biofilm formation on human skin wound models and demonstration of clinically translatable bacteria-specific volatile signatures. *Sci Rep* 2018;8:9431.
 39. Kanji S, Das H. Advances of stem cell therapeutics in cutaneous wound healing and regeneration. *Mediators Inflamm* 2017;2017:5217967.
 40. Abdel-Sayed P, Hirt-Burri N, de Buys Roessingh A, Raffoul W, Applegate LA. Evolution of biological bandages as first cover for burn patients. *Adv Wound Care* 2019;8:555–564.
 41. Qu J, Zhao X, Liang Y, et al. Antibacterial adhesive injectable hydrogels with rapid self-healing, extensibility and compressibility as wound dressing for joints skin wound healing. *Biomaterials* 2018;183:185–199.
 42. Erring M, Gaba S, Mohsina S, Tripathy S, Sharma RK. Comparison of efficacy of silver-nanoparticle gel, nano-silver-foam and collagen dressings in treatment of partial thickness burn wounds. *Burns* 2019;45:1888–1894.
 43. Punjtaewakupt A, Napavichayanun S, Aramwit P. The downside of antimicrobial agents for wound healing. *Eur J Clin Microbiol Inf Dis* 2019;38:39–54.
 44. Dumville JC, Lipsky BA, Hoey C, et al. Topical antimicrobial agents for treating foot ulcers in people with diabetes. *Cochrane Database Syst Rev* 2017;6:CD011038.
 45. Bora I, Demir AB, Uzun P. Nonconvulsive status epilepticus cases arising in connection with cephalosporins. *Epilepsy Behav Case Rep* 2016;6:23–27.
 46. Suemaru K, Yoshikawa M, Aso H, Watanabe M. 5-Fluorouracil exacerbates cefepime-induced convulsions in pentylenetetrazol-kindled mice. *Epilepsy Res* 2019;157:106195.
 47. Triplett JD, Lawn ND, Chan J, Dunne JW. Cephalosporin-related neurotoxicity: metabolic encephalopathy or non-convulsive status epilepticus? *J Clin Neurosci* 2019;67:163–166.
 48. Greenhalgh DG. Topical antimicrobial agents for burn wounds. *Clin Plast Surg* 2009;36:597–606.
 49. Khan MA, Bahadar S, Ullah N, et al. Distribution and antimicrobial resistance patterns of *Clostridium perfringens* isolated from vaccinated and unvaccinated goats. *Small Ruminant Res* 2019;173:70–73.
 50. Oh E, Bae J, Kumar A, Choi H-J, Jeon B. Antioxidant-based synergistic eradication of methicillin-resistant *Staphylococcus aureus*

- (MRSA) biofilms with bacitracin. *Int J Antimicrob Agents* 2018;52:96–99.
51. Jaffe L, Wu SC. Dressings, topical therapy, and negative pressure wound therapy. *Clin Podiatr Med Sur* 2019;36:397–411.
 52. Beers EH. Palliative wound care: less is more. *Surg Clin N Am* 2019;99:899–919.
 53. Rachid A, Christophe M, Marc B-M, et al. Methemoglobinemia by cerium nitrate poisoning. *Burns* 2006;32:1060–1061.
 54. Banaeian S, Sereshti M, Rafieian M, Farahbod F, Kheiri S. Comparison of vaginal ointment of honey and clotrimazole for treatment of vulvo-vaginal candidiasis: a random clinical trial. *J Mycol Med* 2017;27:494–500.
 55. Davey RX, Tong SYC. The epidemiology of *Staphylococcus aureus* skin and soft tissue infection in the southern Barkly region of Australia's Northern Territory in 2017. *Pathology* 2019;51:308–312.
 56. Genuino GAS, Baluyut-Angeles KV, Espiritu APT, Lapitan MCM, Buckley BS. Topical petrolatum gel alone versus topical silver sulfadiazine with standard gauze dressings for the treatment of superficial partial thickness burns in adults: a randomized controlled trial. *Burns* 2014;40:1267–1273.
 57. Pasmooij AMG. Topical gentamicin for the treatment of genetic skin diseases. *J Invest Dermatol* 2018;138:731–734.
 58. Tsai C-C, Yang P-S, Liu C-L, et al. Comparison of topical mupirocin and gentamicin in the prevention of peritoneal dialysis-related infections: a systematic review and meta-analysis. *Am J Sur* 2018;215:179–185.
 59. Zeleníková R, Vyhřádalová D. Applying honey dressings to non-healing wounds in elderly persons receiving home care. *J Tissue Viability* 2019;28:139–143.
 60. Wang C, Guo M, Zhang N, Wang G. Effectiveness of honey dressing in the treatment of diabetic foot ulcers: a systematic review and meta-analysis. *Complement Ther Clin Pract* 2019;34:123–131.
 61. Kiran S, Marwah S, Bansal T, Gupta N. Venous air/oxygen embolism due to hydrogen peroxide in anal fistulectomy. *J Anaesthesiol Clin Pharmacol* 2018;34:555–557.
 62. Ibrahim A, Fagan S, Keaney T, et al. A simple cost-saving measure: 2.5% mafenide acetate solution. *J Burn Care Res* 2014;35:349–353.
 63. Story S, Skriba MJ, Maiti K, et al. Synthesis, antimicrobial activity, attenuation of aminoglycoside resistance in MRSA, and ribosomal A-site binding of pyrene-neomycin conjugates. *Eur J Med Chem* 2019;163:381–393.
 64. Sun P, Yu F, Lu J, et al. In vivo effects of neomycin sulfate on non-specific immunity, oxidative damage and replication of cyprinid herpesvirus 2 in crucian carp (*Carassius auratus gibelio*). *Aquacult Fish* 2019;4:67–73.
 65. Leon-Villalpalos J, Jeschke MG, Herndon DN. Topical management of facial burns. *Burns* 2008;34:903–911.
 66. Thornton Spann C, Taylor SC, Weinberg JM. Topical antimicrobial agents in dermatology. *Dis Mon* 2004;50:407–421.
 67. AbouSamra MM, Basha M, Awad GEA, Mansy SS. A promising nystatin nanocapsular hydrogel as an antifungal polymeric carrier for the treatment of topical candidiasis. *J Drug Deliv Sci Technol* 2019;49:365–374.
 68. Kautz O, Schumann H, Degerbeck F, Venemalm L, Jakob T. Severe anaphylaxis to the antiseptic polyhexanide. *Allergy* 2010;65:1068–1070.
 69. Thomas VM, Brown RM, Ashcraft DS, Pankey GA. Synergistic effect between nisin and polymyxin B against pandrug-resistant and extensively drug-resistant *Acinetobacter baumannii*. *Int J Antimicrob Agents* 2019;53:663–668.
 70. Leung AM, Braverman LE. Consequences of excess iodine. *Nat Rev Endocrinol* 2013;10:136.
 71. Sato S, Miyake M, Hazama A, Omori K. Povidone-iodine-induced cell death in cultured human epithelial HeLa cells and rat oral mucosal tissue. *Drug Chem Toxicol* 2014;37:268–275.
 72. Vogt PM, Reimer K, Hauser J, et al. PVP-iodine in hydrosomes and hydrogel—a novel concept in wound therapy leads to enhanced epithelialization and reduced loss of skin grafts. *Burns* 2006;32:698–705.
 73. Sterling JP. Silver-resistance, allergy, and blue skin: truth or urban legend? *Burns* 2014;40:S19–S23.
 74. Moyano AJ, Mas CR, Colque CA, Smania AM. Dealing with biofilms of *Pseudomonas aeruginosa* and *Staphylococcus aureus*: in vitro evaluation of a novel aerosol formulation of silver sulfadiazine. *Burns* 2020;46:128–135.
 75. Mohseni M, Shamloo A, Aghababaei Z, et al. A comparative study of wound dressings loaded with silver sulfadiazine and silver nanoparticles: in vitro and in vivo evaluation. *Int J Pharm* 2019;564:350–358.
 76. Salazar-Mercado SA, Torres-León CA, Rojas-Suárez JP. Cytotoxic evaluation of sodium hypochlorite, using *Pisum sativum* L as effective bioindicator. *Ecotoxicol Environ Saf* 2019;173:71–76.
 77. Luddin N, Ahmed HMA. The antibacterial activity of sodium hypochlorite and chlorhexidine against *Enterococcus faecalis*: a review on agar diffusion and direct contact methods. *J Conserv Dent* 2013;16:9–16.
 78. Bohaty BR, Choi S, Cai C, Hebert AA. Clinical and bacteriological efficacy of twice daily topical retapamulin ointment 1% in the management of impetigo and other uncomplicated superficial skin infections. *Int J Womens Dermatol* 2015;1:13–20.
 79. Iliescu Nelea M, Paek L, Dao L, et al. In-situ characterization of the bacterial biofilm associated with Xeroform™ and Kaltostat™ dressings and evaluation of their effectiveness on thin skin engraftment donor sites in burn patients. *Burns* 2019;45:1122–1130.
 80. Barillo DJ, Barillo AR, Korn S, Lam K, Attar PS. The antimicrobial spectrum of Xeroform®. *Burns* 2017;43:1189–1194.
 81. Rončević T, Pužina J, Tossi A. Antimicrobial peptides as anti-infective agents in pre-post-antibiotic era? *Int J Mol Sci* 2019;20:5713.
 82. Dubos RJ. Studies on a bactericidal agent extracted from a soil bacillus: I. Preparation of the agent. Its activity in vitro. *J Exp Med* 1939;70:1–10.
 83. Dubos RJ, Hotchkiss RD. The production of bactericidal substances by aerobic sporulating bacilli. *J Exp Med* 1941;73:629–640.
 84. Wang G, Li X, Wang Z. APD3: the antimicrobial peptide database as a tool for research and education. *Nucleic Acids Res* 2016;44:D1087–D1093.
 85. The Antimicrobial Peptide Database (APD). <http://aps.unmc.edu/AP> (last accessed October 1, 2019).
 86. Andersson DI, Hughes D, Kubicek-Sutherland JZ. Mechanisms and consequences of bacterial resistance to antimicrobial peptides. *Drug Resist Updat* 2016;26:43–57.
 87. Kuroda K, Okumura K, Isogai H, Isogai E. The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs. *Front Oncol* 2015;5:144.
 88. Powers J-PS, Hancock REW. The relationship between peptide structure and antibacterial activity. *Peptides* 2003;24:1681–1691.
 89. Khandelia H, Kaznessis YN. Cation-pi interactions stabilize the structure of the antimicrobial peptide indolicidin near membranes: molecular dynamics simulations. *J Phys Chem B* 2007;111:242–250.
 90. Li X, Duan D, Yang J, et al. The expression of human β -defensins (hBD-1, hBD-2, hBD-3, hBD-4) in gingival epithelia. *Arch Oral Biol* 2016;66:15–21.
 91. Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. *Cell Immunol* 2012;280:22–35.
 92. Bergman P, Johansson L, Asp V, et al. *Neisseria gonorrhoeae* downregulates expression of the human antimicrobial peptide LL-37. *Cell Microbiol* 2005;7:1009–1017.
 93. Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Rollman O. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. *Wound Repair Regen* 2014;22:613–621.

94. Du H, Puri S, McCall A, et al. Human salivary protein Histatin 5 has potent bactericidal activity against ESKAPE pathogens. *Front Cell Infect Microbiol* 2017;7:41.
95. Maria-Neto S, de Almeida KC, Macedo MLR, Franco OL. Understanding bacterial resistance to antimicrobial peptides: from the surface to deep inside. *Biochim Biophys Acta* 2015;1848(Pt B): 3078–3088.
96. Belas R, Manos J, Suvanasuthi R. *Proteus mirabilis* ZapA metalloprotease degrades a broad spectrum of substrates, including antimicrobial peptides. *Infect Immun* 2004;72:5159–5167.
97. Overhage J, Campisano A, Bains M, et al. Human host defense peptide LL-37 prevents bacterial biofilm formation. *Infect Immun* 2008;76: 4176–4182.
98. Buch PJ, Chai Y, Goluch ED. Treating polymicrobial infections in chronic diabetic wounds. *Clin Microbiol Rev* 2019;32:e00091-00018.
99. Lee EY, Lee MW, Fulan BM, Ferguson AL, Wong GCL. What can machine learning do for antimicrobial peptides, and what can antimicrobial peptides do for machine learning? *Interface Focus* 2017;7:20160153.
100. Bahar AA, Ren D. Antimicrobial peptides. *Pharmaceuticals (Basel)* 2013;6:1543–1575.
101. Sani M-A, Separovic F. How membrane-active peptides get into lipid membranes. *Acc Chem Res* 2016;49:1130–1138.
102. Sahariah P, Benediktssdóttir BE, Hjalmsdóttir MÁ, et al. Impact of chain length on antibacterial activity and hemocompatibility of quaternary N-alkyl and N,N-dialkyl chitosan derivatives. *Biomacromolecules* 2015;16:1449–1460.
103. Steigbigel RT, Steigbigel NH. Static vs cidal antibiotics. *Clin Infect Dis* 2019;68:351–352.
104. Wenzel M, Rautenbach M, Vosloo JA, et al. The multifaceted antibacterial mechanisms of the pioneering peptide antibiotics tyrocidine and gramicidin S. *mBio* 2018;9:e00802-18.
105. Kane LE, Muzevich KM. Micafungin in the treatment of candiduria: a case series. *Med Mycol Case Rep* 2016;11:5–8.
106. Food and Drug Administration (FDA) Center for drug evaluation and research. Approved drug products with Therapeutic Equivalence Evaluations. <https://www.fda.gov/media/71474/download> (last accessed September 29, 2019).
107. Lei J, Sun L, Huang S, et al. The antimicrobial peptides and their potential clinical applications. *Am J Transl Res* 2019;11:3919–3931.
108. Koo HB, Seo J. Antimicrobial peptides under clinical investigation. *Pept Sci* 2019;111:e24122.
109. Mensa B, Howell GL, Scott R, DeGrado WF. Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. *Antimicrob Agents Chemother* 2014;58:5136–5145.
110. Kuppusamy R, Willcox M, Black DS, Kumar N. Short cationic peptidomimetic antimicrobials. *Antibiotics (Basel)* 2019;8:44.
111. Kudrimoti M, Curtis A, Azawi S, et al. Dusquetide: a novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. *J Biotechnol* 2016;239:115–125.
112. Hamill P, Brown K, Jenssen H, Hancock RE. Novel anti-infectives: is host defence the answer? *Curr Opin Biotechnol* 2008;19:628–636.
113. van der Velden WJFM, van Iersel TMP, Blijlevens NMA, Donnelly JP. Safety and tolerability of the antimicrobial peptide human lactoferrin 1–11 (hLF1–11). *BMC Med* 2009;7:44.
114. Ciumac D, Gong H, Hu X, Lu JR. Membrane targeting cationic antimicrobial peptides. *J Colloid Interface Sci* 2019;537:163–185.
115. U.S. National Library of Medicine. Clinical trials. <https://clinicaltrials.gov/ct2/show/NCT01803035> (last accessed September 29, 2019).
116. Felicio MR, Silva ON, Goncalves S, Santos NC, Franco OL. Peptides with dual antimicrobial and anticancer activities. *Front Chem* 2017;5:5.
117. Boto A, Pérez de la Lastra JM, González CC. The road from host-defense peptides to a new generation of antimicrobial drugs. *Molecules* 2018; 23:311.
118. U.S. National Library of Medicine. Clinical trials. <https://clinicaltrials.gov/ct2/show/results/NCT01594762> (last accessed September 29, 2019).
119. Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of Pexiganan cream. *Clin Infect Dis* 2008;47:1537–1545.
120. Rabanal F, Cajal Y. Recent advances and perspectives in the design and development of polymyxins. *Nat Prod Rep* 2017;34:886–908.
121. Biswalo LS, da Costa Sousa MG, Rezende TMB, Dias SC, Franco OL. Antimicrobial peptides and nanotechnology, recent advances and challenges. *Front Microbiol* 2018;9:855.
122. Mahlapuu M, Håkansson J, Ringstad L, Björn C. Antimicrobial peptides: an emerging category of therapeutic agents. *Front Cell Infect Microbiol* 2016;6:194.
123. Molchanova N, Hansen PR, Franzky H. Advances in development of antimicrobial peptidomimetics as potential drugs. *Molecules* 2017;22:E1430.
124. U.S. National Library of Medicine. Clinical trials. <https://clinicaltrials.gov/ct2/show/NCT02571998> (last accessed September 29, 2019).
125. Martin-Serrano Á, Gómez R, Ortega P, de la Mata FJ. Nanosystems as vehicles for the delivery of antimicrobial peptides (AMPs). *Pharmaceutics* 2019;11:448.
126. Calabretta MK, Kumar A, McDermott AM, Cai C. Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and poly(ethylene glycol) groups. *Biomacromolecules* 2007;8:1807–1811.
127. Lopez AI, Reins RY, McDermott AM, Trautner BW, Cai C. Antibacterial activity and cytotoxicity of PEGylated poly(amidoamine) dendrimers. *Mol Biosyst* 2009;5:1148–1156.
128. Wang B, Navath RS, Menjoge AR, et al. Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. *Int J Pharm* 2010; 395:298–308.
129. Menjoge AR, Navath RS, Asad A, et al. Transport and biodistribution of dendrimers across human fetal membranes: implications for intravaginal administration of dendrimer-drug conjugates. *Biomaterials* 2010;31:5007–5021.
130. Pieters RJ. Intervention with bacterial adhesion by multivalent carbohydrates. *Med Res Rev* 2007;27:796–816.
131. Zeng Y, Kurokawa Y, Win-Shwe TT, et al. Effects of PAMAM dendrimers with various surface functional groups and multiple generations on cytotoxicity and neuronal differentiation using human neural progenitor cells. *J Toxicol Sci* 2016;41:351–370.
132. Stach M, Siriwardena TN, Köhler T, et al. Combining topology and sequence design for the discovery of potent antimicrobial peptide dendrimers against multidrug-resistant *Pseudomonas aeruginosa*. *Angew Chem* 2014;53:12827–12831.
133. Tam JP, Lu Y-A, Yang J-L. Antimicrobial dendrimeric peptides. *Eur J Biochem* 2002;269:923–932.
134. Scorciapino MA, Serra I, Manzo G, Rinaldi AC. Antimicrobial dendrimeric peptides: structure, activity and new therapeutic applications. *Int J Mol Sci* 2017;18:542.
135. Scorciapino Mariano A, Pirri G, Vargiu Attilio V, et al. A novel dendrimeric peptide with antimicrobial properties: structure-function analysis of SB056. *Biophys J* 2012;102:1039–1048.
136. Sowińska M, Laskowska A, Guśpiel A, et al. Bioinspired amphiphilic peptide dendrimers as specific and effective compounds against drug resistant clinical isolates of *E. coli*. *Bioconjugate Chem* 2018;29:3571–3585.
137. Abdel-Sayed P, Kaeppli A, Siriwardena T, et al. Anti-microbial dendrimers against multidrug-resistant *P. aeruginosa* enhance the angiogenic effect of biological burn-wound bandages. *Sci Rep* 2016;6:22020.
138. Pompilio A, Geminiani C, Mantini P, et al. Peptide dendrimers as “lead compounds” for the treatment of chronic lung infections by *Pseudomonas aeruginosa* in cystic fibrosis patients:

- in vitro and in vivo studies. *Infect Drug Resist* 2018;11:1767–1782.
139. Reymond J-L, Bergmann M, Darbre T. Glycopeptide dendrimers as *Pseudomonas aeruginosa* biofilm inhibitors. *Chem Soc Rev* 2013;42:4814–4822.
 140. Vlieghe P, Lisowski V, Martinez J, Khrestchatsky M. Synthetic therapeutic peptides: science and market. *Drug Discov Today* 2010;15:40–56.
 141. Sahariah P, Sørensen KK, Hjälmarsdóttir MÁ, et al. Antimicrobial peptide shows enhanced activity and reduced toxicity upon grafting to chitosan polymers. *Chem Commun (Camb)* 2015; 51:11611–11614.
 142. Pranantyo D, Xu LQ, Kang E-T, Chan-Park MB. Chitosan-based peptidopolysaccharides as cationic antimicrobial agents and antibacterial coatings. *Biomacromolecules* 2018;19:2156–2165.
 143. Costa F, Maia S, Gomes J, Gomes P, Martins MC. Characterization of hLF1–11 immobilization onto chitosan ultrathin films, and its effects on antimicrobial activity. *Acta Biomater* 2014;10: 3513–3521.
 144. Costa FM, Maia SR, Gomes PA, Martins MC. Dhvar5 antimicrobial peptide (AMP) chemoselective covalent immobilization results on higher antiadherence effect than simple physical adsorption. *Biomaterials* 2015;52:531–538.
 145. Yang Z, Liu J, Gao J, Chen S, Huang G. Chitosan coated vancomycin hydrochloride liposomes: characterizations and evaluation. *Int J Pharm* 2015;495:508–515.
 146. Yang K, Gitter B, Rüger R, et al. Antimicrobial peptide-modified liposomes for bacteria targeted delivery of temoporfin in photodynamic antimicrobial chemotherapy. *Photochem Photobiol Sci* 2011;10:1593–1601.
 147. Gupta CM, Haq W. Tuftsin-Bearing Liposomes as Antibiotic Carriers in Treatment of Macrophage Infections. *Methods Enzymol* 2005;391:291–304.
 148. Zhang R, Wu F, Wu L, et al. Novel self-assembled micelles based on cholesterol-modified antimicrobial peptide (DP7) for safe and effective systemic administration in animal models of bacterial infection. *Antimicrob Agents Chemother* 2018;62:e00368-18.
 149. Iooss P, Le Ray AM, Grimandi G, Daculsi G, Merle C. A new injectable bone substitute combining poly(ϵ -caprolactone) microparticles with biphasic calcium phosphate granules. *Biomaterials* 2001;22:2785–2794.
 150. Gavini E, Chetoni P, Cossu M, et al. PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies. *Eur J Pharm Biopharm* 2004;57:207–212.
 151. Piras AM, Maisetta G, Sandreschi S, et al. Chitosan nanoparticles loaded with the antimicrobial peptide temporin B exert a long-term antibacterial activity in vitro against clinical isolates of *Staphylococcus epidermidis*. *Front Microbiol* 2015;6:372.
 152. Almaaytah A, Mohammed GK, Abualhaijaa A, Al-Balas Q. Development of novel ultrashort antimicrobial peptide nanoparticles with potent antimicrobial and antibiofilm activities against multidrug-resistant bacteria. *Drug Des Devel Ther* 2017;11:3159–3170.
 153. d'Angelo I, Casciaro B, Miro A, et al. Overcoming barriers in *Pseudomonas aeruginosa* lung infections: engineered nanoparticles for local delivery of a cationic antimicrobial peptide. *Colloids Surf B Biointerfaces* 2015;135: 717–725.

Abbreviations and Acronyms

AgNO ₃	= silver nitrate
AMP	= antimicrobial peptide
AMPD	= antimicrobial peptide dendrimer
AMR	= antimicrobial resistance
CLSI	= Clinical and Laboratory Standards Institute
ESKAPE	= <i>Enterococcus faecium</i> , <i>Staphylococcus aureus</i> , <i>Klebsiella pneumoniae</i> , <i>Acinetobacter baumannii</i> , <i>Pseudomonas aeruginosa</i> , and <i>Enterobacter</i> species
FDA	= U.S. Food and Drug Administration
Gram (+)	= Gram-positive
Gram (–)	= Gram-negative
H ₂ O ₂	= hydrogen peroxide
hBD	= human β -defensin
HC	= hemolytic concentration
hLF	= human lactoferrin fragment
HNC	= head and neck cancer
I.M.	= intramuscular
I.T.	= intrathecal
I.V.	= intravenous injection
LPS	= lipopolysaccharide
MBC	= minimal bactericidal concentration
MDR	= multidrug resistant
MIC	= minimal inhibitory concentration
MRSA	= methicillin-resistant <i>S. aureus</i>
PAMAM	= poly(amidoamine)
PC	= preclinical
Pg1	= protegrin-1
PHMB	= polyhexa-methylene biguanide
PLGA	= poly(lactide-co-glycolide)
RBC	= red blood cell
TAA	= topical antimicrobials and antiseptics
VRE	= vancomycin-resistant enterococci
WHO	= World Health Organization